Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies

Marta Del Campo; Yolande A.L. Pijnenburg; Alice Chen-Plotkin; David J. Irwin; Murray Grossman; Harry A.M. Twaalfhoven; William T. Hu; Lieke H. Meeter; John van Swieten; Lisa Vermunt; Frans Martens; Annemieke C. Heijboer; Charlotte E. Teunissen

doi:10.3390/biom11101484

Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies

Marta Del Campo^*
, Yolande A.L. Pijnenburg
, Alice Chen-Plotkin
, David J. Irwin
, Murray Grossman
, Harry A.M. Twaalfhoven
, William T. Hu
, Lieke H. Meeter
, John van Swieten
, Lisa Vermunt
, Frans Martens
, Annemieke C. Heijboer
, Charlotte E. Teunissen

^*Corresponding author for this work

Neurology

Vrije Universiteit Amsterdam
CEU Universities
UPenn School of Medicine
Emory University School of Medicine
Rutgers - The State University of New Jersey, New Brunswick
Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Web of Science)

144 Downloads (Pure)

Abstract

Abstract: Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome
study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau
patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the
main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLDTau (n = 23), FTLD-TDP (n = 29) and controls (n = 33) using an automated electro-chemiluminescent
immunoassay. Differences in CSF SHBG levels across groups, as well as its association with CSF
YKL40, pTau181/total-Tau ratio and cognitive function were analyzed. CSF SHBG did not differ
across groups, though a trend towards elevated levels in FTLD-Tau cases compared to FTLD-TDP
and controls was observed. CSF SHBG levels were not associated with either CSF YKL40 or the
p/tTau ratio. They, however, inversely correlated with the MMSE score (r = −0.307, p = 0.011), an
association likely driven by the FTLD-Tau group (r FTLD-Tau = −0.38; r FTLD-TDP = −0.02). CSF
SHBG is not a suitable biomarker to discriminate FTLD-Tau from FTLD-TDP

Original language	English
Article number	1484
Journal	Biomolecules
Volume	11
Issue number	10
DOIs	https://doi.org/10.3390/biom11101484
Publication status	Published - 8 Oct 2021

Bibliographical note

Funding Information:
Funding: M.d.C. is supported by the attraction talent fellowship of Comunidad de Madrid (2018-T2/BMD-11885) and San Pablo CEU University. D.I. is supported by NIH grants P01-AG066597, P30-AG010124. Roche Diagnostics International Ltd. supported the measurements and analysis of CSF SHBG and the APC.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Access to Document

10.3390/biom11101484Licence: CC BY

biomolecules-11-01484-v2Final published version, 712 KBLicence: CC BY
biomolecules-11-01484-v2Licence: CC BY

Cite this

Campo, M. D., Pijnenburg, Y. A. L., Chen-Plotkin, A., Irwin, D. J., Grossman, M., Twaalfhoven, H. A. M., Hu, W. T., Meeter, L. H., Swieten, J. V., Vermunt, L., Martens, F., Heijboer, A. C., & Teunissen, C. E. (2021). Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 11(10), Article 1484. https://doi.org/10.3390/biom11101484

@article{f896b4563d7344eb81bff50575ab694f,

title = "Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies",

abstract = "Abstract: Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLDTau (n = 23), FTLD-TDP (n = 29) and controls (n = 33) using an automated electro-chemiluminescent immunoassay. Differences in CSF SHBG levels across groups, as well as its association with CSF YKL40, pTau181/total-Tau ratio and cognitive function were analyzed. CSF SHBG did not differ across groups, though a trend towards elevated levels in FTLD-Tau cases compared to FTLD-TDP and controls was observed. CSF SHBG levels were not associated with either CSF YKL40 or the p/tTau ratio. They, however, inversely correlated with the MMSE score (r = −0.307, p = 0.011), an association likely driven by the FTLD-Tau group (r FTLD-Tau = −0.38; r FTLD-TDP = −0.02). CSF SHBG is not a suitable biomarker to discriminate FTLD-Tau from FTLD-TDP",

author = "Campo, \{Marta Del\} and Pijnenburg, \{Yolande A.L.\} and Alice Chen-Plotkin and Irwin, \{David J.\} and Murray Grossman and Twaalfhoven, \{Harry A.M.\} and Hu, \{William T.\} and Meeter, \{Lieke H.\} and Swieten, \{John van\} and Lisa Vermunt and Frans Martens and Heijboer, \{Annemieke C.\} and Teunissen, \{Charlotte E.\}",

note = "Funding Information: Funding: M.d.C. is supported by the attraction talent fellowship of Comunidad de Madrid (2018-T2/BMD-11885) and San Pablo CEU University. D.I. is supported by NIH grants P01-AG066597, P30-AG010124. Roche Diagnostics International Ltd. supported the measurements and analysis of CSF SHBG and the APC. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = oct,

day = "8",

doi = "10.3390/biom11101484",

language = "English",

volume = "11",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

Campo, MD, Pijnenburg, YAL, Chen-Plotkin, A, Irwin, DJ, Grossman, M, Twaalfhoven, HAM, Hu, WT, Meeter, LH , Swieten, JV, Vermunt, L, Martens, F, Heijboer, AC & Teunissen, CE 2021, 'Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies', Biomolecules, vol. 11, no. 10, 1484. https://doi.org/10.3390/biom11101484

Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. / Campo, Marta Del; Pijnenburg, Yolande A.L.; Chen-Plotkin, Alice et al.
In: Biomolecules, Vol. 11, No. 10, 1484, 08.10.2021.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies

AU - Campo, Marta Del

AU - Pijnenburg, Yolande A.L.

AU - Chen-Plotkin, Alice

AU - Irwin, David J.

AU - Grossman, Murray

AU - Twaalfhoven, Harry A.M.

AU - Hu, William T.

AU - Meeter, Lieke H.

AU - Swieten, John van

AU - Vermunt, Lisa

AU - Martens, Frans

AU - Heijboer, Annemieke C.

AU - Teunissen, Charlotte E.

N1 - Funding Information: Funding: M.d.C. is supported by the attraction talent fellowship of Comunidad de Madrid (2018-T2/BMD-11885) and San Pablo CEU University. D.I. is supported by NIH grants P01-AG066597, P30-AG010124. Roche Diagnostics International Ltd. supported the measurements and analysis of CSF SHBG and the APC. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/10/8

Y1 - 2021/10/8

N2 - Abstract: Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLDTau (n = 23), FTLD-TDP (n = 29) and controls (n = 33) using an automated electro-chemiluminescent immunoassay. Differences in CSF SHBG levels across groups, as well as its association with CSF YKL40, pTau181/total-Tau ratio and cognitive function were analyzed. CSF SHBG did not differ across groups, though a trend towards elevated levels in FTLD-Tau cases compared to FTLD-TDP and controls was observed. CSF SHBG levels were not associated with either CSF YKL40 or the p/tTau ratio. They, however, inversely correlated with the MMSE score (r = −0.307, p = 0.011), an association likely driven by the FTLD-Tau group (r FTLD-Tau = −0.38; r FTLD-TDP = −0.02). CSF SHBG is not a suitable biomarker to discriminate FTLD-Tau from FTLD-TDP

AB - Abstract: Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLDTau (n = 23), FTLD-TDP (n = 29) and controls (n = 33) using an automated electro-chemiluminescent immunoassay. Differences in CSF SHBG levels across groups, as well as its association with CSF YKL40, pTau181/total-Tau ratio and cognitive function were analyzed. CSF SHBG did not differ across groups, though a trend towards elevated levels in FTLD-Tau cases compared to FTLD-TDP and controls was observed. CSF SHBG levels were not associated with either CSF YKL40 or the p/tTau ratio. They, however, inversely correlated with the MMSE score (r = −0.307, p = 0.011), an association likely driven by the FTLD-Tau group (r FTLD-Tau = −0.38; r FTLD-TDP = −0.02). CSF SHBG is not a suitable biomarker to discriminate FTLD-Tau from FTLD-TDP

UR - https://www.scopus.com/pages/publications/85116514065

U2 - 10.3390/biom11101484

DO - 10.3390/biom11101484

M3 - Article

C2 - 34680117

AN - SCOPUS:85116514065

SN - 2218-273X

VL - 11

JO - Biomolecules

JF - Biomolecules

IS - 10

M1 - 1484

ER -

Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this